Arvinas Reports Q4 and Full Year 2019 Financial Results

- March 16th, 2020

Arvinas reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

Arvinas (NASDAQ:ARVN) reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

As quoted in the press release:

“2019 was an exciting year for Arvinas, marked by tremendous clinical and corporate progress. We were delighted to present the first human clinical data from targeted protein degraders along with preclinical data demonstrating the brain-penetrating potential of our PROTAC® protein degraders. These data underscore the potential of our platform to create safe and well-tolerated drugs for the treatment of a variety of life-threatening diseases,” said John Houston, Ph.D., Chief Executive Officer of Arvinas.

Click here to read the full press release.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus Investing: An Overview for Investors

 
COVID-19 continues to impact markets across the world. Get INN’s overview of coronavirus investing.
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply